Abstract: Disclosed is the use of a gold cluster or a gold cluster-containing substance in the preparation of a drug for preventing and/or treating glaucoma.
Abstract: There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.
Abstract: The present invention provides a 2-pyridone derivative having a structure represented by formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. Activity experiment results show that the 2-pyridone derivative provided in the present invention has higher activity and selectivity, and can be used to treat thyroid hormone receptor-related diseases.
Abstract: The present invention relates to various crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide. The present invention also relates to pharmaceutical compositions comprising the crystalline forms.
Abstract: The present invention relates to a compound, a pharmaceutical composition comprising the compound, the method for the preparation thereof, and the use thereof as TRK inhibitors. The compound is a compound as shown in the following formula I, and isomers, prodrugs, solvates, stable isotopic derivatives or pharmaceutically acceptable salts thereof. The present invention also relates to use of the compound in treating or preventing diseases mediated by TRK, such as cancers, and method for treating such diseases using the compounds of the present invention.
Type:
Grant
Filed:
June 25, 2019
Date of Patent:
January 23, 2024
Assignee:
Beijing Innocare Pharma Tech Co., Ltd.
Inventors:
Norman Xianglong Kong, Chao Zhou, Zhixiang Zheng
Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
Type:
Grant
Filed:
May 25, 2022
Date of Patent:
December 12, 2023
Assignee:
Guangzhou Innocare Pharma Tech Co., Ltd
Inventors:
Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni
Abstract: The present invention provides a method for improving the stability of pramipexole or its salt preparation, and further provides a pramipexole hydrochloride oral liquid with excellent stability and oral absorption effect. The pramipexole hydrochloride oral liquid of the present invention is prepared through a simple process, and shows bioequivalence with the tablet containing pramipexole hydrochloride. The invention perfectly realizes multi-dose administration of pramipexole hydrochloride and improves the compliance and accessibility of medication for patients.
Abstract: Provided are a bispecific antibody binding to CD20 and CD3 and the use thereof. The bispecific antibody contains a first binding domain which binds to CD20 on the surface of a target cell and a second binding domain which binds to CD3 on the surface of T cell. The bispecific antibody is well tolerated, can effectively eliminate B cells under low-dose conditions, and has both better efficacy and safety than similar antibodies.
Abstract: The present invention provides use of phenylquinolinone derivative or flavonoid derivative for neuropathic pain. The phenylquinolinone derivative or flavonoid derivative include pharmaceutically acceptable salts thereof. The compound of the present invention is a histamine H3 receptor antagonist, has a different mechanism of action from existing drugs, and can be used in the preparation of drugs for treating neuropathic pain diseases. The effect of the compound of the present invention for treating neuropathic pain is superior to that of amitriptyline, gabapentin, pregabalin and carbamazepine. Therefore, the compound of the present invention has a better treatment effect, and has the characteristics of a small dosage, good drug efficacy, high bioavailability and high safety. Compared with opioids, the compound of the present invention has no addiction property, and is a very effective drug for treating neuropathic pain diseases. Therefore, the compound has a great prospect in clinical application.
Abstract: There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers.
Abstract: There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis.
Type:
Grant
Filed:
December 17, 2018
Date of Patent:
August 8, 2023
Assignee:
RISEN (SUZHOU) PHARMA TECH CO., LTD.
Inventors:
Xianqi Kong, Jiasheng Lu, Jiamin Gu, Xiang Ji, Daiqiang Hu, Xiuchun Zhang, Xinyong Lv, Jinchao Ai, Dongdong Wu, Lin Wang, Dongqing Zhu, Xiaolin He
Abstract: Provided herein is novel compounds of formula (I), (II), (III), (IV), and (V) as described in the specification, and pharmaceutically acceptable salts, solvates, and prodrugs and compositions thereof, and methods of measuring hedgehog pathway activation in tumor cells, examining tumor cell proliferation, differentiation and apoptosis and using the compounds and pharmaceutical compositions disclosed for treatment of diseases and disorders associated with the hedgehog signaling pathway.
Abstract: A traditional Chinese medicine composition, and preparation method, and application thereof. The traditional Chinese medicine composition includes the following raw medicines in parts by weight: 10-35 parts of root of Chinese thorowax, 5-25 parts of immature bitter orange, 3-20 parts of fresh root and rhizome of sorrel rhubarb, 3-20 parts of root of baikal skullcap, 3-20 parts of white peony root, 3-15 parts of dried ginger, 5-20 parts of leech, 3-20 parts of root of ural licorice, 3-20 parts of root pilose asiabell, 3-20 parts of rhizome of largehead atractylodes, and 3-25 parts of tuber of pinellia. The traditional Chinese medicine composition has excellent effects in lowering blood lipids and cholesterol levels, particularly in lowering blood triglyceride. The traditional Chinese medicine composition also has excellent effects in slowing formation of atherosclerotic plaques, clearing the atherosclerotic plaques, and preventing and treating atherosclerosis.
Abstract: The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof.
Type:
Grant
Filed:
August 18, 2021
Date of Patent:
March 21, 2023
Assignee:
RISEN (SUZHOU) PHARMA TECH CO., LTD.
Inventors:
Jiasheng Lu, Jiamin Gu, Daiqiang Hu, Xianqi Kong
Abstract: There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis.
Type:
Grant
Filed:
December 17, 2018
Date of Patent:
February 28, 2023
Assignee:
RISEN (SUZHOU) PHARMA TECH CO., LTD.
Inventors:
Jiasheng Lu, Jiamin Gu, Xiang Ji, Daiqiang Hu, Xiuchun Zhang, Xinyong Lv, Jinchao Al, Dongdong Wu, Xianqi Kong, Lin Wang, Dongqing Zhu, Xiaolin He
Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 7, 2021
Date of Patent:
February 7, 2023
Assignee:
Beijing Innocare Pharma Tech Co., Ltd.
Inventors:
Xiangyang Chen, Yingxiang Gao, Norman Xianglong Kong
Abstract: CD73 (also known as ecto-5?-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I and pharmaceutically acceptable esters or salts thereof.
Type:
Grant
Filed:
December 23, 2020
Date of Patent:
December 20, 2022
Assignee:
RISEN (SUZHOU) PHARMA TECH CO., LTD.
Inventors:
Jiasheng Lu, Jiamin Gu, Gang Chen, Feng Zhou, Qiguo Zhang, Xuli Wang, Xiang Ji, Lin Wang, Xianqi Kong
Abstract: The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is provided at a suitable particle size, and the D90 thereof <50 ?m. With regard to the drug-containing particles obtained by the present invention, a pharmaceutical preparation formed therefrom exhibits rapid release characteristics in an in vitro dissolution test and exhibits considerable advantages in pharmacokinetics in vivo, showing a greater degree (AUC) and rate (Cmax) of drug absorption.
Abstract: Disclosed is the use of a gold cluster or a gold cluster-containing substance in the preparation of a drug for preventing and/or treating glaucoma.
Abstract: Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and the use thereof are described. Compounds of the present invention have a structure represented by formula (I). Further disclosed are preparation methods for said compounds, and the use of said compounds as KRASG12C inhibitors. The compounds have an excellent ability to selectively inhibit KRASG12C, improved pharmacodynamic and pharmacokinetic performance, and reduced toxic side effects.